Scott Rocklage has more than thirty years of experience in the medical field. He has held several administrative positions such as serving as the chief executive officer and chairman of Cubist Pharmaceutical, CEO, and president of Nycomed Salutar and various R&D posts at Salutar and Catlytica. He joined 5AM Ventures in 2003 as a partner and became a managing partner I 2004. Scott Rocklage’s expert leadership skills have led to the FDA approval of three drugs, namely, Cubicin, Teslasan, and Omniscan.
5AM Ventures specializes in helping companies launch medical breakthroughs by investing in promising and unique projects. They have a team of highly skilled and well-informed investment professionals who use proven scientific and legal measures to analyze a company’s products. They input into the company’s efforts of developing scientific solutions by strategizing its business sector, managing the human staff, and organizing fundraising initiatives.
Scott revealed that the founding team branded the firm as 5AM Ventures since it deals with the operatives of establishing a company. He explained that setting up a company is the first stage of business, as is the 5 a.m hour. Scott works with entrepreneurs in all sectors of the business, such as scientists, business executives, and physicians to create innovative medical solutions for ignored medical conditions. He values entrepreneurship and explains that working for an established firm is not a creative way to grow and gain invaluable skills.
Scott Rocklage is in awe of the rapid developments in cancer treatment, citing that being able to customize a patient’s treatment module according to their genes is a breakthrough that will only yield more progress. In an interview with IdeaMensch, Scott revealed that capitalizing on the human resource is the foundation of his business. He pointed out that he has learned to pick out the best candidates to maximize the productivity of the firm.
Scott has an undergraduate of chemistry from the University of California and a doctorate in the same field from Massachusetts Institute of Technology. In 2005, Rocklage won a Nobel Prize in Chemistry for his remarkable research in MIT at the Richard R. Schrock laboratory. Rocklage holds more than 30 patents and has over 100 peer-reviewed scientific publications.